CapVest Partners LLP has officially announced the completion of its acquisition of a majority stake in STADA Arzneimittel AG, a leading German-based healthcare and pharmaceutical company. The transaction was finalized after satisfying all customary closing conditions and obtaining necessary regulatory approvals.
Strategic significance and performance:
-
STADA’s Global Reach: Currently employing nearly 12,000 people, STADA operates as a diversified global healthcare platform specializing in Consumer Healthcare, Generics, and Specialty Pharmaceuticals, with products sold in over 100 countries.
-
Record Financials: For the 2025 fiscal year, the company reported record-breaking revenues of €4.3 billion (a 6% year-on-year increase) and an all-time high adjusted EBITDA of €961 million.
-
Future Growth Path: The partnership aims to accelerate STADA’s global expansion by deploying capital toward organic growth and new strategic acquisitions, leveraging CapVest’s extensive expertise in the healthcare sector.
CapVest is a premier international private equity investor known for partnering with ambitious companies in resilient, non-discretionary industries. The majority acquisition of STADA is expected to further transform the company’s scale, reinforcing its position as a dominant player in the global pharmaceutical landscape.